Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05187546
Other study ID # LMT-02-01-21
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date March 10, 2022
Est. completion date December 2023

Study information

Verified date July 2023
Source Life Molecular Imaging SA
Contact Audrey Perrotin, PhD
Phone +49 (0)30 461 1246 03
Email GRA@life-mi.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The overall goal of this protocol is to evaluate the imaging characteristics of [18F]PI-2620 using positron emission tomography (PET) in patients with progressive supranuclear palsy, Richardson's syndrome (PSP-RS)


Description:

The imaging characteristics of [18F]PI-2620 using positron emission tomography (PET) in patients with progressive supranuclear palsy, Richardson's syndrome (PSP-RS) will be evaluated by a) determining the test-retest variability of the [18F]PI-2620 binding parameters in brain of patients with PSP-RS and non-demented controls (NDC).


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date December 2023
Est. primary completion date September 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria (for all subjects) - Males and females aged 50-80 years - Able to understand, sign and date written informed consent - Signed and dated written informed consent obtained from the subject - The subject has an appropriate caregiver capable of accompanying subject, if necessary - Have an Montreal Cognitive Assessment (MoCa) score = 27 - Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral salpingectomy or bilateral oophorectomy) or post-menopausal for at least 1 year (no menses for 12 months without an alternative medical cause). If they are of child-bearing potential, must commit to use of a highly effective contraceptive measure for the duration of the study - Male subjects and their partners of childbearing potential must commit to the use of a highly effective method of contraception for a minimum of 90 days following each PET scan - Male subjects must commit to not donate sperm for a minimum of 90 days after each PET scan - Willing and able to cooperate with study procedures including lying flat and still on the scanning bed for 60 minutes Inclusion criteria for non-demented controls (NDC) - Healthy with no clinically relevant finding on physical examination at screening - No cognitive impairment from neuropsychological battery as judged by the investigator - A brain MRI without evidence of significant neurological pathology - A beta-amyloid Neuraceq® PET demonstrating a negative beta-amyloid status - No signs of movement disorder as judged by Progressive Supranuclear Palsy Rating Scale (PSPRS), Movement Disorder Society - Unified Parkinson's Disability Rating Scale (MDS-UPDRS) and Progressive Supranuclear Palsy Clinical Deficits Scale (PSP-CDS) Inclusion Criteria for patients with probable PSP-RS - Patients with a clinical diagnosis of probable PSP-RS based on the Movement Disorder Society criteria (Höglinger et al., 2017) - Medications taken for symptomatic treatment of PSP must be maintained on a stable dosage regimen for at least 30 days before the [18F]PI-2620 PET imaging visits Exclusion Criteria (for all subjects) - Hemoglobin value < 10 g/dL - Laboratory tests with clinically significant abnormalities and/or clinically significant unstable medical illness equivalent to CTC v5.0 (common toxicity criteria) toxicities greater than grade 2 - Evidence of clinically significant disease that is expected to interfere with cognitive assessments or the ability to complete the study procedures - Subjects with clinically significant renal and hepatic dysfunction as judged by the investigator - Known hypersensitivity to the active substance or to any of the excipients of [18F]PI-2620 - Known hypersensitivity to the active substance or to any of the excipients of Neuraceq®, for NDC only - Subject has received an investigational drug including treatments targeting Amyloid-beta or tau within 3 months of screening - Pregnant (or having the intention of getting pregnant), lactating or breastfeeding - Unsuitable veins for repeated venipuncture. - Subject has a contraindication to blood sampling and/or arterial cannulation, including but not limited to peripheral vascular disease, Raynaud's phenomenon as determined by abnormal Allen's test or abnormal coagulation profile at screening - MRI exclusion criteria include but not limited to: Findings of cerebrovascular disease (more than two lacunar infarcts, any territorial infarct >1 cm3, or deep white matter abnormality corresponding to an overall Fazekas scale of 3 with at least one confluent hyperintense lesion on the Fluid-Attenuated Inversion Recovery (FLAIR) sequence that is 20 mm in any dimension), infectious disease, space-occupying lesions, normal pressure hydrocephalus or any other abnormalities associated with Central Nervous System (CNS) disease - Implants such as implanted cardiac pacemakers or defibrillators, insulin pumps, cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS aneurysm clips and other medical implants that have not been certified for MRI, or history of claustrophobia in MRI - Unwilling and/or unable to cooperate with study procedures

Study Design


Intervention

Drug:
[18F]-PI2620
[18F]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of [18F]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).

Locations

Country Name City State
Germany Ludwig-Maximilians-Universität München Munich

Sponsors (1)

Lead Sponsor Collaborator
Life Molecular Imaging GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Test-retest variability of the [18F]PI-2620 binding parameters in brain of patients with PSP-RS and non-demented controls Test-retest variability of [18F]PI-2620 accumulation will be analyzed using quantification The duration of the study for participants may be up to 74 days
Primary Number of adverse events Safety will be evaluated by collection of Adverse Events. The duration of the study for participants may be up to 74 days
Secondary Compare quantification in terms if test-retest variability in PSP-RS and NDC Comparison of quantification in terms of test-retest variability in PSP and NDC. The ability of [18F]PI-2620 to discriminate between PSP-RS and NDC will be assessed. The duration of the study for participants may be up to 74 days
Secondary Correlate radioligand binding in PSP-RS with clinical scales Correlation of radioligand binding with clinical scales in PSP-RS will be analyzed The duration of the study for participants may be up to 74 days
See also
  Status Clinical Trial Phase
Completed NCT04096651 - Pathophysiology of Gait and Posture in Progressive Supranuclear Palsy N/A
Recruiting NCT02194816 - Modifiable Variables in Parkinsonism (MVP)
Completed NCT00703677 - A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Phase 1/Phase 2
Completed NCT00382824 - Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP) N/A
Completed NCT04184063 - Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) Phase 2
Recruiting NCT04706234 - Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
Recruiting NCT04472130 - Neurodegenerative Diseases Registry
Recruiting NCT04139551 - Oxford Study of Quantification in Parkinsonism
Completed NCT02734485 - Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy N/A
Completed NCT01110720 - Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy Phase 2/Phase 3
Completed NCT01174771 - Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration N/A
Completed NCT00465790 - Research of Biomarkers in Parkinson Disease Phase 0
Completed NCT02460094 - Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy Phase 1
Active, not recruiting NCT04993768 - A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP) Phase 2
Recruiting NCT03225144 - Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Completed NCT03058965 - Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain Early Phase 1
Recruiting NCT02605785 - A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy N/A
Completed NCT01353183 - Analysis of the Enteric Nervous System Using Colonic Biopsies N/A
Completed NCT00385710 - Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine) Phase 2
Recruiting NCT05260151 - Tau Protein and SV2a Imaging in Patients With Tau Protein-related Diseases